Keith M Kerr

Summary

Affiliation: University of Aberdeen
Country: UK

Publications

  1. ncbi request reprint Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma
    Keith M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen, UK
    J Pathol 203:638-44. 2004
  2. pmc The role of DNA methylation in the development and progression of lung adenocarcinoma
    Keith M Kerr
    Department of Pathology, Aberdeen Royal Infirmary, Link Building, Foresterhill, Aberdeen, AB25 2ZN, UK
    Dis Markers 23:5-30. 2007
  3. doi request reprint Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
    K M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, UK
    Ann Oncol 27:iii16-iii24. 2016
  4. ncbi request reprint Classification of lung cancer: proposals for change?
    Keith M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, UK
    Arch Pathol Lab Med 136:1190-3. 2012
  5. doi request reprint Personalized medicine for lung cancer: new challenges for pathology
    Keith M Kerr
    Aberdeen University Medical School, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
    Histopathology 60:531-46. 2012
  6. pmc Pulmonary preinvasive neoplasia
    K M Kerr
    Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Foresterhill, Aberdeen AB25 2ZD, UK
    J Clin Pathol 54:257-71. 2001
  7. doi request reprint Pulmonary adenocarcinomas: classification and reporting
    Keith M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
    Histopathology 54:12-27. 2009
  8. doi request reprint Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens
    Peh Sun Loo
    Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, UK
    J Thorac Oncol 5:442-7. 2010
  9. doi request reprint The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York Dept d Anatomie et Cytologie Pathologiques, CHU Albert Michallon, University Joseph Fourier INSERM U823 Institut Albert Bonniot, Grenoble, France Department of Pathology, Royal Brompton Hospital, London, United Kingdom Department of Pathology, Aichi Cancer Center, Nagoya, Japan Department of Radiology, Columbia University Medical Center, New York, New York Department of Pathology, Ichan School of Medicine at Mt Sinai, New York, New York Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania Sullivan Nicolaides Pathology, The John Flynn Hospital, Tugun, Queensland, Australia Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi University of Colorado Cancer Center UCHSC, Aurora, Colorado Department of Pathology, The JFCR Cancer Institute, Tokyo, Japan Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, Scotland
    J Thorac Oncol 10:1243-60. 2015
  10. ncbi request reprint Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society
    Sinchita Roy-Chowdhuri
    From the Department of Pathology, University of Texas MD Anderson Cancer Center, Houston Dr Roy Chowdhuri the Department of Pathology, University of Colorado Cancer Center, Denver Dr Aisner the Department of Pathology, University of Texas Medical Branch, Galveston Dr Allen the Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York Dr Beasley the Department of Pathology, Weill Cornell Medical College, New York Drs Borczuk and Cagle the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas Dr Cagle the Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil Dr Capelozzi the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Dr Dacic the Department of Pathology, University Health Network, Princess Margaret Cancer Centre, and the University of Toronto, Toronto, Ontario, Canada Drs da Cunha Santos and Tsao the Department of Pathology, Massachusetts General Hospital, and Harvard Medical School, Boston Drs Hariri and Mino Kenudson the Department of Pathology, Aberdeen University Medical School, and Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, United Kingdom Dr Kerr the Department of Biopathology, Centre Leon Berard, Lyon, and J Fourier University, Institut National de la Santé et de la Recherche Médicale Institut Albert Bonniot, Grenoble, Department of Urology
    Arch Pathol Lab Med . 2016

Detail Information

Publications25

  1. ncbi request reprint Expression of Fhit, cell adhesion molecules and matrix metalloproteinases in atypical adenomatous hyperplasia and pulmonary adenocarcinoma
    Keith M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen, UK
    J Pathol 203:638-44. 2004
    ..Loss of MMP-2 and TIMP-2 in stromally invasive tumour may reflect a particular role for MMP-2 at the BAC stage, with later down-regulation of this particular enzyme...
  2. pmc The role of DNA methylation in the development and progression of lung adenocarcinoma
    Keith M Kerr
    Department of Pathology, Aberdeen Royal Infirmary, Link Building, Foresterhill, Aberdeen, AB25 2ZN, UK
    Dis Markers 23:5-30. 2007
    ....
  3. doi request reprint Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
    K M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, UK
    Ann Oncol 27:iii16-iii24. 2016
    ..As scientific understanding and diagnostic technology develops, ALK testing will continue to be an evolving and challenging paradigm. ..
  4. ncbi request reprint Classification of lung cancer: proposals for change?
    Keith M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, UK
    Arch Pathol Lab Med 136:1190-3. 2012
    ..The huge increase in data on the molecular biology of lung cancer has improved our understanding of these diseases, has driven improved therapy for some patients, and must be reflected in the way lung cancer is classified...
  5. doi request reprint Personalized medicine for lung cancer: new challenges for pathology
    Keith M Kerr
    Aberdeen University Medical School, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
    Histopathology 60:531-46. 2012
    ..This extended diagnostic requirement from increasingly limited material provided by minimally invasive biopsy techniques poses major challenges for pathology...
  6. pmc Pulmonary preinvasive neoplasia
    K M Kerr
    Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Foresterhill, Aberdeen AB25 2ZD, UK
    J Clin Pathol 54:257-71. 2001
    ....
  7. doi request reprint Pulmonary adenocarcinomas: classification and reporting
    Keith M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, UK
    Histopathology 54:12-27. 2009
    ..The emerging clinical and prognostic relevance of a number of histological features in these complex tumours strengthens the argument in favour of including quantitative detail of pattern sub-types in reports on resected tumours...
  8. doi request reprint Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens
    Peh Sun Loo
    Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, UK
    J Thorac Oncol 5:442-7. 2010
    ..Histochemical staining for mucin and immunohistochemical (IHC) identification of NSCLC subtype-associated markers could help predict the final subtype of resected NSCLCs diagnosed as NSCLC-NOS on preoperative bronchial biopsy samples...
  9. doi request reprint The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York Dept d Anatomie et Cytologie Pathologiques, CHU Albert Michallon, University Joseph Fourier INSERM U823 Institut Albert Bonniot, Grenoble, France Department of Pathology, Royal Brompton Hospital, London, United Kingdom Department of Pathology, Aichi Cancer Center, Nagoya, Japan Department of Radiology, Columbia University Medical Center, New York, New York Department of Pathology, Ichan School of Medicine at Mt Sinai, New York, New York Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania Sullivan Nicolaides Pathology, The John Flynn Hospital, Tugun, Queensland, Australia Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi University of Colorado Cancer Center UCHSC, Aurora, Colorado Department of Pathology, The JFCR Cancer Institute, Tokyo, Japan Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, Scotland
    J Thorac Oncol 10:1243-60. 2015
    ..to sclerosing pneumocytoma, (10) changing the name hamartoma to "pulmonary hamartoma," (11) creating a group of PEComatous tumors that include (a) lymphangioleiomyomatosis, (b) PEComa, benign (with clear cell tumor as a variant) and ..
  10. ncbi request reprint Biomarker Testing in Lung Carcinoma Cytology Specimens: A Perspective From Members of the Pulmonary Pathology Society
    Sinchita Roy-Chowdhuri
    From the Department of Pathology, University of Texas MD Anderson Cancer Center, Houston Dr Roy Chowdhuri the Department of Pathology, University of Colorado Cancer Center, Denver Dr Aisner the Department of Pathology, University of Texas Medical Branch, Galveston Dr Allen the Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York Dr Beasley the Department of Pathology, Weill Cornell Medical College, New York Drs Borczuk and Cagle the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas Dr Cagle the Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil Dr Capelozzi the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Dr Dacic the Department of Pathology, University Health Network, Princess Margaret Cancer Centre, and the University of Toronto, Toronto, Ontario, Canada Drs da Cunha Santos and Tsao the Department of Pathology, Massachusetts General Hospital, and Harvard Medical School, Boston Drs Hariri and Mino Kenudson the Department of Pathology, Aberdeen University Medical School, and Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, United Kingdom Dr Kerr the Department of Biopathology, Centre Leon Berard, Lyon, and J Fourier University, Institut National de la Santé et de la Recherche Médicale Institut Albert Bonniot, Grenoble, Department of Urology
    Arch Pathol Lab Med . 2016
    ..This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era...
  11. doi request reprint Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial
    Marianne C Nicolson
    Thoracic Oncology, Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, United Kingdom
    J Thorac Oncol 8:930-9. 2013
    ..This phase II study explored this association prospectively at the protein and mRNA-expression level...
  12. ncbi request reprint Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application
    Russell D Petty
    Department of Oncology, Aberdeen and Oncology Research Group, Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, United Kingdom
    Clin Cancer Res 10:3237-48. 2004
    ..Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease...
  13. doi request reprint In compressed lung tissue microscopic sections of adenocarcinoma in situ may mimic papillary adenocarcinoma
    Erik Thunnissen
    From the Departments of Pathology Drs Thunnissen and Beliën, Radiology Dr Lely, and Surgery Dr Hartemink, VU University Medical Center, Amsterdam, the Netherlands the Department of Pathology, Aberdeen Royal Infirmary, Aberdeen University Medical School, Aberdeen, Scotland Dr Kerr the Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea Dr Chung the Department of Pathology, Fox Chase Cancer Center, Philadelphia, Pennsylvania Dr Flieder the Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Japan Dr Noguchi the Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan Dr Yatabe the Department of Pathology, University Health Network Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada Drs Hwang and Tsao and the Department of Pathology, Symbiant Medical Center Alkmaar, Alkmaar, the Netherlands Dr Meijer Jorna
    Arch Pathol Lab Med 137:1792-7. 2013
    ..Surgical removal and pathologic handling of lung tissue has a compressive effect upon its architecture. The effect of surgical atelectasis on morphology has not been examined in depth, especially with respect to lung adenocarcinomas...
  14. doi request reprint Quantitative analysis of tumor in bronchial biopsy specimens
    Caroline L Coghlin
    Department of Pathology, Aberdeen Royal Infirmary and Aberdeen University Medical School, Aberdeen, United Kingdom
    J Thorac Oncol 5:448-52. 2010
    ..We analyzed a series of 100 bronchial biopsy specimens in lung cancer patients to assess the frequency and quantity of tumor present in biopsy samples...
  15. doi request reprint Liquid Biopsy in Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society
    Lynette M Sholl
    From the Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts Drs Sholl and Vivero the Department of Pathology, University of Colorado Cancer Center, Denver Dr Aisner the Department of Pathology, The University of Texas Medical Branch, Galveston Dr Allen the Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York Dr Beasley the Department of Pathology, Weill Cornell Medical College, New York, New York, and the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas Dr Cagle the Department of Pathology, University of Sao Paulo Medical School, Sao Paulo, Brazil Dr Capelozzi the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Dr Dacic the Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston Drs Hariri and Mino Kenudson the Department of Pathology, Aberdeen University Medical School and Aberdeen Royal Infirmary, Foresterhill, Aberdeen, Scotland, United Kingdom Dr Kerr the Department of Biopathology, Centre Leon Berard, Lyon, France, and J Fourier University INSERM U 823 Institut A Bonniot, Grenoble, France Dr Lantuejoul the Department of Pathology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois Dr Raparia the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, Department of Urology
    Arch Pathol Lab Med 140:825-9. 2016
    ..Ultimately, notwithstanding the enthusiasm encompassing liquid biopsy, its clinical utility remains unproven. ..
  16. doi request reprint Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
    Keith M Kerr
    Department of Pathology, Aberdeen University Medical School, Aberdeen Royal Infirmary, Aberdeen, United Kingdom Department of Pathology, University Health Network Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada Department of Histopathology, Royal Brompton and Harefield Hospitals NHS Foundation Trust, London, United Kingdom Department of Pathology and Molecular Diagnostics, Aichi Cancer Centre, Nagoya, Japan Department of Pathology, University of Texas MD Anderson Cancer Centre, Houston, Texas and Division of Medical Oncology, Department of Pathology, University of Colorado Denver, Aurora, Colorado
    J Thorac Oncol 10:985-9. 2015
    ....
  17. doi request reprint Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study
    Erik Thunnissen
    Departments of Pathology and Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, The Netherlands Department of Pathology, Faculty of Medicine, Tsukuba, Japan Rutgers New Jersey Medical School, Newark, New Jersey Department of Pathology, Mount Sinai Medical Center, New York, New York Elisabeth Brambilla, CHU Albert Michallon, Institut de Biologie, Département d Anatomie et Cytologie Pathologiques, Grenoble Cedex, France Brigham and Women s Hospital, Boston, Massachusetts Department of Pathology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania Piedmont Pathology Associates, Hickory, North Carolina, and University of North Carolina, Chapel Hill, North Carolina Department of Medicine and Pathology, University of Colorado Cancer Center, Aurora, Colorado Division of Pathology, The Cancer Institute, Japanese Foundation Cancer Research, Tokyo, Japan Department of Pathology, Aberdeen Royal Infirmary, Aberdeen, United Kingdom Department of Pathology, CHU A Michallon
    J Thorac Oncol 9:1354-62. 2014
    ....
  18. doi request reprint Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
    Keith M Kerr
    From the Department of Pathology, Aberdeen University School of Medicine Dr Kerr, and the Department of Oncology Dr Nicolson, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
    Arch Pathol Lab Med 140:249-54. 2016
    ..One such mechanism is the adoption of immune checkpoints to inhibit the host immune response. Immune checkpoint inhibitors show great promise in the treatment of advanced non-small cell lung cancer...
  19. doi request reprint Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?
    Keith M Kerr
    From the Department of Pathology, Aberdeen University School of Medicine, Aberdeen Royal Infirmary, Aberdeen, Scotland, United Kingdom Dr Kerr and
    Arch Pathol Lab Med 140:326-31. 2016
    ..This paper discusses some of the issues, challenges, hazards, and possible solutions that have recently emerged in this most complex interface between cancer therapeutics and laboratory biomarker testing. ..
  20. pmc EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey
    Yasushi Yatabe
    Department of Pathology and Molecular Diagnostics, Aichi Cancer Center, Nagoya, Japan Department of Pathology, Aberdeen University Medical School, Aberdeen, United Kingdom KalGen Laboratory, Stem cell and Cancer Institute SCI, Jakarta, Indonesia School of Medicine, Monash University Malaysia and Sime Darby Medical Center, Kuala Lumpur, Malaysia Center for Gene and Protein Research, Hanoi Medical University, Hanoi, Vietnam Department of Pathology, Fudan University Shanghai Cancer Center Institute of Pathology, Fudan University, Shanghai, China Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan Research and Biotechnology Division, St Luke s Medical Center, Quezon City and COS CENSER, De La Salle University, Manila, Philippines Department of Pathology, National Cancer Center, Goyang si, Gyeonggi Do, Korea Department of Pathology, Singapore General Hospital, Singapore, Singapore Chulalongkorn GenePRO Center, Chulalongkorn Hospital, Bangkok, Thailand Seoul National University Bundang Hospital, Seoul, Ibaraki 304-8506
    J Thorac Oncol 10:438-45. 2015
    ..Although EGFR mutation testing has been adopted by many laboratories in Asia, data are lacking on the proportion of NSCLC patients tested in each country, and the most commonly used testing methods...
  21. doi request reprint Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer
    Gordon Urquhart
    School of Medicine and Dentistry, University of Aberdeen, Foresterhill Healthcare Campus, Foresterhill, Aberdeen, Scotland, United Kingdom and Departments of Oncology and Pathology Aberdeen Royal Infirmary, Foresterhill Healthcare Campus, Foresterhill, Aberdeen, Scotland, United Kingdom
    J Thorac Oncol 8:1502-9. 2013
    ..This independent prospective study was designed to confirm the predictive utility of SB3...
  22. ncbi request reprint Spontaneous dissection of an anomalous systemic artery in the lung during pregnancy: a rare cause of hemoptysis
    Shafaque Shaikh
    Department of Cardiothoracic Surgery, Aberdeen Royal Infirmary, Aberdeen, United Kingdom
    Ann Thorac Surg 82:725-6. 2006
    ..This article aims to discuss the clinical presentation, diagnostic curiosity, management using a minimally invasive technique (video-assisted thoracoscopic lobectomy), and finally the histopathologic findings...
  23. ncbi request reprint Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer
    Russell D Petty
    Oncology Research Group, Department of Medicine and Therapeutics, Institute of Medical Sciences, School of Medicine, University of Aberdeen, Aberdeen, nited Kingdom
    J Clin Oncol 24:1729-44. 2006
    ..Insight into clinical response to platinum-based chemotherapy (PBC) in non-small-cell lung cancer (NSCLC)...
  24. ncbi request reprint Evaluation of NQO1 gene expression and variant allele in human NSCLC tumors and matched normal lung tissue
    Jill M Kolesar
    School of Pharmacy, University of Wisconsin Madison, 777 Highland Avenue, Madison, WI 53706 1515, USA
    Int J Oncol 21:1119-24. 2002
    ..007), suggesting NQO1 may be important in chemosensitivity as well as the pathogenesis of lung cancer and NQO1 genotyping may be a useful component of pharmacogenetic strategies for the treatment of NSCLC...
  25. ncbi request reprint Changing trends in incidence of lung cancer by histologic type in Scotland
    Elaine F Harkness
    ARC Epidemiology Unit, Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
    Int J Cancer 102:179-83. 2002
    ..Changes in histologic types are unlikely to be solely due to diagnostic advances. Rates of adenocarcinoma have increased steadily over time, and this may be due to changes in cigarette design during the 1950s...